A neural interface device that comprises an implantable microelectrode body. The implantable microelectrode body includes a neural interface probe, which includes a thin film metal trace connected to an interface pad and an amorphous silicon carbide insulation. The amorphous silicon carbide insulation surrounds the thin film metal trace to form an outside surface of the neural interface probe. The interface pad is exposed to an ambient environment of the neural interface probe through an opening in the amorphous silicon carbide insulation. Methods of manufacturing the neural interface device are disclosed.

Disclosed herein are single use indicators and methods for employing the same. Such indicators and their uses are directed towards identifying the discharge status of single procedure devices, which are typically, but not limited to, medical devices.

Methods for improving the antibacterial and/or bone-forming characteristics of biomedical implants and related implants manufactured according to such methods. In some implementations, a biomedical implant may comprise a composite of a silicon nitride ceramic powder dispersed within a poly-ether-ether-ketone (PEEK) or a poly-ether-ketone-ketone (PEKK) substrate material. In some implementations, the biomedical implant may be 3D printed.

A stent having an inner surface and an outer surface, the stent comprising a coating composition comprising a platelet-activated adhesive on at least a portion of the outer surface thereof.

The invention relates to the use of a polyphosphate salt as procoagulant mediator agent in medical devices or pharmaceutical compositions and the respective polyphosphate-containing medical devices and pharmaceutical compositions. The invention further relates to a method for preparing an aqueous fibroin solution by use of a microwave treatment. The invention further relates to a fibroin-containing structure produced or obtainable by the preparation method of the invention. The invention further comprises subsequent process steps leading to solidified fibroin products and to the use of said products for medical treatment.

In some illustrative examples, a medical drape suitable for treating a tissue site may include an adherent surface including first adherent force profile oriented along a first axis and a second adherent force profile oriented along a second axis. The first adherent force profile may have an average force less than an average force of the second adherent force profile. Other apparatuses, systems, and methods are also provided.

The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.

A wearable device is described. The wearable device includes a housing having a back cover, and an optical mask on first portions of the back cover. The back cover includes a set of windows, with a first subset of windows in the set of windows being defined by an absence of the optical mask on second portions of the back cover, and a second subset of windows in the set of windows being inset in a set of openings in the back cover. An optical barrier surrounds each window in the second subset of windows. A set of light emitters is configured to emit light through at least some of the windows in the set of windows. A set of light detectors is configured to receive light through at least some of the windows in the set of windows.

Zen Roller is manufactured to our exact specifications so the Himalayan salt barrel does not break during machining or use. The other two pieces (a surgical steel clasp, and a handle) are designed to hold the barrel while allowing for rotation—and for easy removal and/or replacement. In addition, the outer surface of the Himalayan salt barrel is highly polished to our exact specifications so it is non-abrasive to the skin.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.